Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Am J Transplant. 2019 Jan;19(1):89-97. doi: 10.1111/ajt.14987. Epub 2018 Jul 25.
Antibody-mediated rejection is responsible for 30%-50% of renal graft failures. Differentiation of B cells into antibody-producing plasmablasts depends on the collaboration of follicular helper T cells (Tfh). We analyzed circulating Tfh (cTfh) in kidney recipients and studied cTfh relationship with anti-HLA antibody production and graft outcome. cTfh were longitudinally analyzed in a prospective cohort of patients (n = 206), pre- and posttransplantation. Clinical data, HLA sensitization, and cTfh function were recorded. Both pretransplant and 6-month posttransplant cTfh were able to derive IgG-producing plasmablasts. Pretransplant cTfh was decreased in patients, especially in those who received dialysis. However, these cells were increased in patients with previous allograft or transfusions and in HLA-sensitized recipients. After transplantation cTfh expanded, significantly more in patients who developed de novo anti-HLA antibodies than in patients who remained unsensitized. Augmented pretransplant cTfh positively correlated with higher intensity of pretransplant anti-HLA class I and with de novo anti-HLA class I and anti-HLA class II antibodies. Consistently, pretransplantation cTfh were higher in patients who experienced acute rejection (HR = 1.14 [1.04-1.25]). Thus, we show a role for Tfh in anti-HLA sensitization and rejection. Multicenter studies with additional patient cohorts are needed to validate these results. Immunosuppressive drugs targeting Tfh could be useful to improve outcomes.
抗体介导的排斥反应是导致 30%-50%肾移植失败的原因。B 细胞分化为产生抗体的浆母细胞依赖于滤泡辅助 T 细胞(Tfh)的协作。我们分析了肾移植受者循环中的 Tfh(cTfh),并研究了 cTfh 与抗 HLA 抗体产生和移植物结局的关系。在一项前瞻性队列研究中,对 206 例患者进行了 cTfh 的纵向分析,包括移植前和移植后。记录了临床数据、HLA 致敏和 cTfh 功能。移植前和移植后 6 个月的 cTfh 均能衍生产生 IgG 的浆母细胞。与未接受透析的患者相比,移植前 cTfh 在患者中减少,尤其是在接受透析的患者中。然而,在有既往同种异体移植或输血以及 HLA 致敏的受者中,这些细胞增加。移植后 cTfh 扩增,在发生新的抗 HLA 抗体的患者中明显多于未致敏的患者。移植前 cTfh 增加与移植前抗 HLA Ⅰ类抗体的强度呈正相关,与新的抗 HLA Ⅰ类和抗 HLA Ⅱ类抗体呈正相关。同样,在经历急性排斥反应的患者中,移植前 cTfh 更高(HR=1.14[1.04-1.25])。因此,我们证明了 Tfh 在抗 HLA 致敏和排斥反应中的作用。需要进行更多患者队列的多中心研究来验证这些结果。针对 Tfh 的免疫抑制药物可能有助于改善结局。